• Nitin M. Bhand
• Geetanjali P. More
• Tushar M.Phalke
• Gaurav A. Mahajan
• Smita S.Pimple

Traditional surgical or chemoradiotherapeutic methods typically cannot eradicate metastatic cancer cells, and disease recurrence is very common after treatment. On the other hand, stem cell-based therapies are becoming more and more promising for the treatment of cancer. By homing in on and concentrating on both primary and metastatic tumour foci, stem cells can serve as innovative delivery systems. In preclinical animal models, stem cells modified to stably express different cytotoxic drugs reduce tumour sizes and lengthen longevity. They have also been used as virus and nanoparticle carriers to lessen the negative effects of treatment and improve the effectiveness of initial therapies. Additionally, stem cells can be used in immunotherapy, cancer stem cell-targeted therapy, and applications for anticancer drug screening. However, although treating human malignancies with stem cells.

Cancer, stem cell, connexins, chemotherapy

"HLA-E (Human Leukocyte Antigen-E): Promising Biological agent for Cancer Mitigation", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 5, page no.o554-o562, May-2023, Available :http://www.jetir.org/papers/JETIR2305F73.pdf

"HLA-E (Human Leukocyte Antigen-E): Promising Biological agent for Cancer Mitigation", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 5, page no. ppo554-o562, May-2023, Available at : http://www.jetir.org/papers/JETIR2305F73.pdf